The neurobiology of glucocerebrosidase-associated parkinsonism: A positron emission tomography study of dopamine synthesis and regional cerebral blood flow

Brain

Volumn 135, Issue 8, 2012, Pages 2440-2448

  Goker Alpan, Ozlem ^a   Masdeu, Joseph C ^b   Kohn, Philip D ^b   Ianni, Angela ^b   Lopez, Grisel ^a   Groden, Catherine ^a   Chapman, Molly C ^b   Cropp, Brett ^b   Eisenberg, Daniel P ^b   Maniwang, Emerson D ^a   Davis, Joie ^a   Wiggs, Edythe ^c   Sidransky, Ellen ^a   Berman, Karen F ^b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

brain imaging; genetic risk; lysosomal storage disorders; Parkinson disease; positron emission tomography (PET)

Indexed keywords

GLUCOSYLCERAMIDASE;

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; FAMILY HISTORY; FEMALE; GAUCHER DISEASE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROBIOLOGY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 84864659715     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws174     Document Type: Article

References (39)

1. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012; 78: 1434-40.
2. Bharucha NE, Stokes L, Schoenberg BS, Ward C, Ince S, Nutt JG, et al. A case-control study of twin pairs discordant for Parkinson disease: a search for environmental risk factors. Neurology 1986; 36: 284-8.
3. Brockmann K, Srulijes K, Hauser AK, Schulte C, Csoti I, Gasser T, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77: 276-80.
4. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy-and Alzheimer-type pathologies in Parkinson disease dementia: which is more important? Brain 2011; 134: 1493-505.
5. Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Risk tables for parkinsonism and Parkinson disease. J Clin Epidemiol 2002; 55: 25-31.
6. Fahn S, Marsden C, Calne D, Goldstein M, editors. Recent developments in Parkinson disease. Vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987.
7. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007; 27: 10365-71.
8. Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science 1988; 241: 462-4.
9. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008; 65: 1353-7.
10. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010; 120: 641-9.
11. Haber SN, Fudge JL, McFarland NR. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 2000; 20: 2369-82.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
14. Khan NL, Scherfler C, Graham E, Bhatia KP, Quinn N, Lees AJ, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 2005; 64: 134-6.
15. Kochan NA, Valenzuela M, Slavin MJ, McCraw S, Sachdev PS, Breakspear M. Impact of load-related neural processes on feature binding in visuospatial working memory. PLoS One 2011; 6: e23960.
16. Kono S, Shirakawa K, Ouchi Y, Sakamoto M, Ida H, Sugiura T, et al. Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. J Neurol Sci 2007; 252: 181-4.
17. Kraoua I, Stirnemann J, Ribeiro MJ, Rouaud T, Verin M, Annic A, et al. Parkinsonism in Gaucher disease type 1: ten new cases and a review of the literature. Mov Disord 2009; 24: 1524-30.
18. Lavenex P, Suzuki WA, Amaral DG. Perirhinal and parahippocampal cortices of the macaque monkey: projections to the neocortex. J Comp Neurol 2002; 447: 394-420.
19. Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson disease genetics: the PDGene database. PLoS Genet 2012; 8: e1002548.
20. Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 2009; 50: 1638-45.
21. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson disease: test-retest reproducibility. J Cereb Blood Flow Metab 2007; 27: 597-605.
22. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146: 37-52.
23. Moore RY, Whone AL, McGowan S, Brooks DJ. Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Res 2003; 982: 137-45.
24. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-9.
25. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson disease. Brain 2009; 132: 1783-94.
26. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, et al. Missing pieces in the Parkinson disease puzzle. Nat Med 2010; 16: 653-61.
27. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson disease. Neuron 2004; 44: 595-600.
28. Pavese N, Khan NL, Scherfler C, Cohen L, Brooks DJ, Wood NW, et al. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an (18)F-Dopa PET progression study. Mov Disord 2009; 24: 2260-6.
29. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45: 577-82.
30. Postuma RB, Gagnon JF, Montplaisir J. Clinical prediction of Parkinson disease: planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry 2010; 81: 1008-13.
31. Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR, et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis 2011; 46: 95-102.
32. Saunders-Pullman R, Hagenah J, Dhawan V, Stanley K, Pastores G, Sathe S, et al. Gaucher disease ascertained through a Parkinson center: imaging and clinical characterization. Mov Disord 2010; 25: 1364-72.
33. Seto-Salvia N, Pagonabarraga J, Houlden H, Pascual-Sedano B, Dols-Icardo O, Tucci A, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson disease course. Mov Disord 2012; 27: 393-9.
34. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson disease. N Engl J Med 2009; 361: 1651-61.
35. Silbert LC, Kaye J. Neuroimaging and cognition in Parkinson disease dementia. Brain Pathol 2010; 20: 646-53.
36. Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson disease. Lancet Neurol 2011; 10: 987-1001.
37. Tayebi N, Reissner KJ, Lau EK, Stubblefield BK, Klineburgess AC,Martin BM, et al. Genotypic heterogeneity and phenotypic variation among patients with type 2 Gaucher disease. Pediatr Res 1998; 43: 571-8.
38. Westbroek W, Gustafson AM, Sidransky E. Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med 2011; 17: 485-93.
39. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004; 82: 192-207.